Palo Alto Networks Dodges $100M Cybersecurity Patent Case – Law360
Palo Alto Networks Dodges $100M Cybersecurity Patent Case Law360
PATENT NEWS
-
In: PATENT NEWS
-
In: PATENT NEWS
Proteomics International Secures Australian Patent for OxiDx Test – TipRanks
Proteomics International Secures Australian Patent for OxiDx Test TipRanks
-
In: PATENT NEWS
Inventor Assignment of Patent Application – Practical Law Canada – Thomson Reuters
A standard patent application and invention assignment conveying all rights in the patent application, inventions disclosed in the application, …
-
In: PATENT NEWS
CureVac up 13% as court upholds validity of patent in BioNTech spat – Seeking Alpha
CureVac up 13% as court upholds validity of patent in BioNTech spat Seeking Alpha
-
In: PATENT NEWS
“Navigating AI’s Impact on Life Sciences and Patent Law” – Marshall, Gerstein & Borun LLP
… intellectual property. “AI implementation in life sciences raises various patent law considerations, including patent subject matter eligibility …
-
In: PATENT NEWS
Ford’s Fake Shifter Patent Doubles Down On The Worst Trend In Modern EVs – Yahoo Autos
Ford’s Fake Shifter Patent Doubles Down On The Worst Trend In Modern EVs Yahoo Autos
-
In: PATENT NEWS
Proposed Bills Limit Pharmaceutical Patents: Panacea for Patients or Poison for Pharmaceutical Producers? – Crowell & Moring LLP
Proposed Bills Limit Pharmaceutical Patents: Panacea for Patients or Poison for Pharmaceutical Producers? Crowell & Moring LLP
-
In: PATENT NEWS
WIPO Future of Transportation: Registered Design Trends – Intellectual Property Law
The World Intellectual Property Organisation (WIPO) has recently released its report on technology trends in the future of transportation.
-
In: PATENT NEWS
CureVac Wins Patent Ruling Against BioNTech – TipRanks
CureVac Wins Patent Ruling Against BioNTech TipRanks
-
In: PATENT NEWS
CureVac Wins Key mRNA Patent Battle Against BioNTech in Europe | CVAC Stock News
CureVac (NASDAQ:CVAC) has achieved a significant legal victory as the European Patent Office (EPO) largely dismissed BioNTech SE’s opposition to …